Citi lowered the firm’s price target on 10x Genomics (TXG) to $23 from $35 and keeps a Buy rating on the shares post the Q3 report. The company lowered the fiscal 2024 guide by $50M at the midpoint, implying flat sequential revenue in Q4, well below consensus, the analyst tells investors in a research note. The firm says weakness in the quarter was largely attributed to disruptions driven by commercial and organizational changes on top of challenging macro conditions.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter